Juno Therapeutics
Bristol Myers Squibb Nabs FDA Accelerated Approval for Breyanzi in Follicular Lymphoma
The agency approved the autologous CAR T-cell therapy after around 96 percent of patients in the Phase II TRANSCEND-FL trial responded to it.
The agency approved the autologous CAR T-cell therapy after around 96 percent of patients in the Phase II TRANSCEND-FL trial responded to it.